SWS Partners’s Guardant Health GH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$11.2M Sell
74,582
-4,899
-6% -$533K 2.42% 9
2026
Q1
$7.34M Buy
79,481
+2,272
+3% +$228K 1.81% 10
2025
Q4
$7.89M Sell
77,209
-17,347
-18% -$1.55M 1.9% 11
2025
Q3
$5.91M Buy
94,556
+1,479
+2% +$80.5K 1.44% 16
2025
Q2
$4.84M Sell
93,077
-11,740
-11% -$524K 1.31% 18
2025
Q1
$4.47M Sell
104,817
-16,071
-13% -$693K 1.47% 14
2024
Q4
$3.69M Buy
120,888
+37,126
+44% +$1.04M 1.12% 20
2024
Q3
$1.92M Buy
83,762
+4,905
+6% +$139K 0.61% 66
2024
Q2
$2.28M Buy
78,857
+33,446
+74% +$779K 0.68% 59
2024
Q1
$937K Sell
45,411
-560
-1% -$12K 0.28% 89
2023
Q4
$1.24M Sell
45,971
-724
-2% -$19K 0.41% 80
2023
Q3
$1.38M Buy
46,695
+2,663
+6% +$93.6K 0.51% 77
2023
Q2
$1.58M Sell
44,032
-460
-1% -$13.2K 0.57% 75
2023
Q1
$1.04M Buy
44,492
+3,391
+8% +$96.9K 0.39% 88
2022
Q4
$1.12M Buy
41,101
+9,666
+31% +$442K 0.53% 70
2022
Q3
$1.69M Buy
31,435
+5,970
+23% +$306K 0.78% 55
2022
Q2
$1.03M Buy
25,465
+10,467
+70% +$519K 0.86% 55
2022
Q1
$995K Buy
+14,998
New +$1.03M 0.65% 65

Other funds holding GH

SWS Partners's GH Position: Q2 2026 in Review

SWS Partners reduced its Guardant Health (GH) stake by 6.2% in Q2 2026, selling an estimated $533K and leaving 74,582 shares worth $11.2M. The position accounts for 2.42% of the portfolio, ranked #9.

SWS Partners first reported a position in GH in Q1 2022 and has held it in 18 quarters since. 190 funds tracked by Wall St. Rank hold GH as of Q2 2026.

  • SWS Partners held 74,582 shares of Guardant Health worth $11.2M as of Q2 2026.
  • SWS Partners sold 4,899 Guardant Health shares in Q2 2026, an estimated $533K.
  • Guardant Health made up 2.42% of SWS Partners's portfolio in Q2 2026, its #9 holding.
  • SWS Partners first reported a position in Guardant Health in Q1 2022 and has held it in 18 quarters since.
  • 190 funds tracked by Wall St. Rank held Guardant Health as of Q2 2026.

Based on SWS Partners's 13F filing for Q2 2026, filed 3 Aug 2026.